Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
September 27 2023 - 9:00AM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company advancing a diverse pipeline of cell
therapies for patients with solid tumors, announced today that six
abstracts highlighting its broad pipeline of clinical and
preclinical product candidates as well as a shortened TIL
manufacturing process have been accepted for presentation at the
38th Annual Meeting of the Society for Immunotherapy of Cancer
(SITC) taking place in San Diego, Nov. 1-5, 2023.
“Our presentations at SITC highlight the
progress we are making on several fronts to advance new product
candidates and technologies designed to generate potent and durable
cell therapies for patients with solid tumors,” stated Dr. Gary
Lee, chief scientific officer at Lyell. “At SITC, we look forward
to sharing new preclinical findings on product candidates and
emerging technologies, data on our Epi-R P2 manufacturing process
which is designed to shorten TIL product delivery time to patients,
and highlighting the design of our two ongoing Phase 1 clinical
trials in progress.”
Four presentations highlight new nonclinical data from pipeline
product candidates and research programs, including a new
technology being advanced through a collaboration with Outpace to
enable context-dependent, localized IL-12 activity to enhance solid
tumor T cell therapies; and Lyell’s novel Epi-R P2 manufacturing
process to shorten manufacturing time for tumor infiltrating
lymphocyte (TIL) therapy.
Two additional presentations highlight the
design of Lyell’s ongoing Phase 1 clinical trials in progress:
LYL797, a ROR1-targeted CAR T-cell therapy being evaluated in a
Phase 1 trial in patients with relapsed refractory triple-negative
breast cancer and non-small cell lung cancer, and LYL845, a tumor
infiltrating lymphocyte (TIL) therapy being evaluated in a Phase 1
trial in advanced solid tumors.
Details on the six poster presentations are
below:
Epi-R™ P2 protocol produces a scalable polyclonal TIL
product with a greater expansion success rate across hot and cold
tumors in shorter culture time
- Presentation Date & Time: Friday, Nov. 3, 12–1:30 p.m. and
5:10–6:40 p.m.
- Abstract Number: 379
Preclinical development of LYL119, a ROR1-targeted CAR
T-cell product incorporating four novel T-cell reprogramming
technologies to overcome barriers to effective cell therapy for
solid tumors
- Presentation Date & Time: Saturday, Nov. 4, 2023,
11:55–1:25 p.m. and 7–8:30 p.m.
- Abstract No.: 278
Protein design and inducible expression allow
context-dependent, localized IL-12 activity to enhance solid tumor
T cell therapies
- Presentation Date & Time: Friday, Nov. 3, 12–1:30 p.m. and
5:10–6:40 p.m.
- Abstract No.: 1047
Rejuvenation of
tumor-infiltrating
lymphocytes (TIL) through Partial
Reprogramming
- Presentation Date & Time: Friday, Nov. 3, 2023, 12–1:30
p.m. and 5:10–6:40 p.m.
- Abstract No.: 393
Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell
therapy enhanced with genetic and epigenetic reprogramming, in
advanced triple-negative breast cancer (TNBC) and non-small cell
lung cancer (NSCLC)
- Presentation Date & Time: Saturday, Nov. 4, 2023,
11:55–1:25 p.m. and 7–8:30 p.m.
- Abstract Number: 754
Phase 1 trial of LYL845, an autologous
tumor-infiltrating lymphocyte (TIL) therapy enhanced with
epigenetic reprogramming, for the treatment of advanced solid
tumors
- Presentation Date & Time: Friday, Nov. 3, 2023,
12–1:30 p.m. and 5:10–6:40 p.m.
- Abstract No.: 747
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company advancing a diverse pipeline of cell therapies for patients
with solid tumors. Lyell is currently enrolling a Phase 1 clinical
trial evaluating a ROR1-targeted CAR T-cell therapy in patients
with relapsed refractory triple-negative breast cancer (TNBC) and
non-small cell lung cancer (NSCLC) and a second Phase 1 clinical
trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL)
in patients with advanced melanoma, NSCLC and colorectal cancer.
The technologies powering its product candidates are designed to
address barriers that limit consistent and long-lasting responses
to cell therapy for solid tumors: T-cell exhaustion and lack of
durable stemness, which includes the ability to persist and
self-renew to drive durable tumor cytotoxicity. Lyell is applying
its proprietary ex vivo genetic and epigenetic reprogramming
technologies to address these barriers in order to develop new
medicines with improved durable clinical outcomes. Lyell is based
in South San Francisco, California with facilities in Seattle and
Bothell, Washington. To learn more, please visit www.lyell.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements expressed or implied
in this press release include, but are not limited to, statements
regarding: Lyell’s anticipated progress, business plans, business
strategy and planned clinical trials; the growing pipeline and
potential clinical benefits and therapeutic potential of Lyell’s
product candidates; the potential for the Epi-R P2 manufacturing
process to produce a scalable polyclonal TIL product with a greater
expansion success rate across hot and cold tumors in shorter
culture time; Lyell’s collaboration with Outpace Bio and the
potential to enable context-dependent, localized IL-12 activity to
enhance solid tumor T cell therapies; the potential of Lyell’s
reprogramming technologies to overcome primary barriers to
successful adoptive cell therapy in solid tumors to improve
clinical responses in patients; the potential for Lyell’s
rejuvenation of TIL through partial reprogramming; and other
statements that are not historical fact. These statements are based
on Lyell’s current plans, objectives, estimates, expectations and
intentions, are not guarantees of future performance and inherently
involve significant risks and uncertainties. Actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, but are not limited to, risks and
uncertainties related to: macroeconomic conditions and the
lingering effects of the COVID-19 pandemic; geopolitical
instability; Lyell’s ability to submit planned INDs or initiate and
execute clinical trials on the anticipated timelines, if at all;
Lyell’s limited experience as a company in enrolling and conducting
clinical trials, and lack of experience in completing clinical
trials; Lyell’s ability to manufacture and supply its product
candidates for its clinical trials; the nonclinical profiles of
Lyell’s product candidates not translating in clinical trials; the
potential for results from clinical trials to differ from
preclinical, early clinical, preliminary or expected results;
significant adverse events, toxicities or other undesirable side
effects associated with Lyell’s product candidates; the significant
uncertainty associated with Lyell’s product candidates ever
receiving any regulatory approvals; Lyell’s ability to obtain,
maintain or protect intellectual property rights related to its
product candidates; the sufficiency of Lyell’s capital resources
and need for additional capital to achieve its goals; and other
risks, including those described under the heading “Risk Factors”
in Lyell’s Annual Report on Form 10-K for the year ended December
31, 2022, filed with the Securities and Exchange Commission (SEC)
on February 28, 2023, and the Quarterly Report on Form 10-Q for the
quarter ended June 30, 2023, filed with the SEC on August 8,
2023. Forward-looking statements contained in this press release
are made as of this date, and Lyell undertakes no duty to update
such information except as required under applicable law.
Contact:
Ellen RoseSenior Vice President, Communications
and Investor Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Apr 2024 to May 2024
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From May 2023 to May 2024